Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.

SERVICIO

Financiamiento, deuda y mercados de capitales

PARTES

“It was particularly pleasing to see the level of support received for this financing, reinforcing confidence in SNG001, our wholly-owned drug and potential breakthrough treatment for COVID-19 patients. Oaklins’ team has always been supportive and built a good register of institutions in March which was broadened further in this funding. It was a very successful fundraising and the level of demand was such that we were comfortably able to increase the size of the funding. Having demonstrated the great promise of SNG001 in hospitalized COVID-19 patients earlier this year, we now have the resources to be able to rapidly progress this potential breakthrough treatment in such a critical area of unmet need.”

Richard Marsden

CEO, Synairgen plc

Contáctese con el equipo de la transacción

Geoff Nash

Director

Londres, Reino Unido
Oaklins Cavendish

Ver perfil Contáctenos

Transacciones relacionadas

Cerbios-Pharma has been acquired by HAS Healthcare

Salud

Cerbios-Pharma has been acquired by HAS Healthcare

Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

Private Equity | Servicios de Construcción e Ingeniería | Energía | TMT

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.

Gewiss S.p.A. has completed a mandatory public tender offer for Beghelli S.p.A.

Otras Industrias

Gewiss S.p.A. has completed a mandatory public tender offer for Beghelli S.p.A.

Gewiss S.p.A. has successfully finalized a mandatory public tender offer for Beghelli S.p.A.